How do Biohaven's 2024 expenses compare to 2023?

Biohaven's 2024 expenses, particularly in Research and Development (R&D) and Selling, General, and Administrative (SG&A), have shown significant increases compared to 2023. Here's a detailed comparison:

1. **Research and Development (R&D) Expenses**:
- In 2023, Biohaven's R&D expenses were $373.28 million.
- In 2024, the R&D expenses increased to $795.87 million.
- This indicates a substantial rise in Biohaven's investment in R&D, suggesting an expansion in their drug development pipeline or increased focus on innovation.
2. **Selling, General, and Administrative (SG&A) Expenses**:
- The data for SG&A expenses is not available for 2023 and 2024 separately, as it is combined with R&D expenses in the report period ending on December 31st.
- However, the overall increase in expenses from $373.28 million in 2023 to $795.87 million in 2024 suggests that SG&A expenses have also likely increased, given the overall growth in Biohaven's operating expenses.

Biohaven's increased expenses reflect a period of significant growth and investment in both drug development and commercial operations. The company's commitment to R&D is likely a strategic move to bolster its product pipeline and maintain its position in the competitive biopharmaceutical sector.